Camelia Deak

The debate continues regarding the benefits and timing of immunotherapy infusions. Non -inferiority of late vs early administration (i-TIMES study). Reassuring for our current clinical practices…@peters_solange #ELCC2026

Day 2 of #ELCC26 @myESMO was a blast! 💥 Great insights at the #ESMOYOC Mentorship Session “From trainee to thoracic oncologist: Building your career roadmap” with @peters_solange and @gerryhanna. Thank you 👏 Stay tuned and follow YOCs in the upcoming session!

A successful starting #ESMOYOC event of #ELCC26 with Vesalius talk for finding the your niche in thoracic oncology by @stephanieplsaw 🇸🇬 @NReguart 🇪🇸 @BenjaminBesseMD 🇫🇷 @DoctorJSpicer 🇨🇦 Excellent insights deserve #YoungOncologists to learn from our international experts 🤩

The #OncoAlert5k 🚨Berlin🇩🇪 HUGE THANKS to all of our Friends We Are ALL OncoAlert 🌐 @DrVilmaPBarcia @benjiwal @vibasilios @marcoscl @sevincballi @SandroCavallero @Gino_K_In_USC @MayanaNavarro @DonjetaZeqa @LouisaHempel @CameliaDeak @CameliaDeak @CathyEngMD @rowela_pfizer @milosicevic @LaurenMachos #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @bmassutis @matteolambe @Icro_Meattini

📣 #ESMOAcademy24 kicking off today in Zurich exploring key topics in #medicaloncology, such as methodology and interpretation of clinical trials, standard of care and future perspectives in the main tumour types, pharmacokinetics and drug interactions. 🔗ow.ly/rGi350SZfIv